Shopping Cart 0
Cart Subtotal
USD 0

Affimed GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Affimed GmbH (Affimed), formerly Affimed Therapeutics AG, a subsidiary of Affimed NV, is a clinical stage biopharmaceutical company which discovers and develops targeted cancer immunotherapies. The company's pipeline product candidates include AFM11, AFM12, AFM13, AFM21 and AFM22, among others. Its AFM13 is in Phase I trials for the treatment of Hodgkin's lymphoma; and AFM11 is in late formal pre-clinical development for the treatment of non-Hodgkin's lymphoma. Affimed's discovery portfolio also includes AFM15, HSAxCD3 in preclinical trials, and others. The company has operations with offices in Czech Republic and the US. Affimed is headquartered in Heidelberg, Baden-Wurttemberg, Germany.

Affimed GmbH-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Affimed GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Affimed GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Affimed GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Affimed GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Affimed GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Affimed GmbH, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Amphivena Therapeutics Raises USD 14 Million In Series A Financing 11

Affimed Therapeutics Raises USD 20.2 Million In Series D Financing 12

Equity Offering 14

Affimed Raises USD21.8 Million in Private Placement of Shares 14

Affimed Therapeutics Raises USD56 Million in IPO 15

Acquisition 17

Janssen Biotech Enters Into Option To Acquire Amphivena From Affirmed Therapeutics 17

Affimed GmbH-Key Competitors 18

Affimed GmbH-Key Employees 19

Affimed GmbH-Locations And Subsidiaries 20

Head Office 20

Recent Developments 21

Financial Announcements 21

Aug 08, 2018: Affimed reports financial results for second quarter 2018 and operational progress 21

May 15, 2018: Affimed Reports Financial Results for First Quarter 2018 24

Mar 20, 2018: Affimed Reports Financial Results for Fourth Quarter and Year End 2017 26

Corporate Communications 28

Mar 19, 2018: Affimed Appoints Dr. Leila Alland as Chief Medical Officer 28

Product News 29

May 03, 2018: Affimed Introduces ROCK Platform for Tailored Immune Cell Engagers 29

03/01/2017: Affimed to Present Data on AFM13 at the AACR Annual Meeting 2017 30

03/01/2017: Affimed to Present Data on lead candidate AFM24 at the AACR Annual Meeting 2017 31

03/01/2017: Affimed to Present Data on lead candidate AFM26 at the AACR Annual Meeting 2017 32

03/01/2017: Affimed to Present Data on Monoclonal Antibodies to Target HLA-A2 and CD3 for Oncology at the AACR Annual Meeting 2017 33

Clinical Trials 34

Jun 15, 2018: Affimed Announces Updated Data of AFM13 in Combination with Keytruda (Pembrolizumab) in Patients with Relapsed/Refractory Hodgkin Lymphoma Presented at EHA 34

Mar 15, 2018: Affimed to Present Data on AFM24 at AACR Annual Meeting 2018 35

Feb 01, 2018: Affimed Reports New Data for AFM13 from Two Separate Clinical Trials in Hodgkin and CD30-Positive Lymphomas 36

Dec 11, 2017: Affimed Presents Data From Phase 1b Combination Study of AFM13 With Pembrolizumab at ASH 38

Dec 11, 2017: Affimed Presents Preclinical Data on AFM26 at American Society of Hematology (Ash) Annual Meeting and Exposition 2017 40

Jun 27, 2017: Affimed Presents Preclinical Data on AFM24 at EACR-AACR-SIC 2017 41

Jun 27, 2017: Affimed Presents Preclinical Data on AFM26 at EACR-AACR-SIC 2017 42

Jun 06, 2017: Affimed Presents Data on First-in-Class BCMA-Targeting Immune Cell Engager AFM26 at ASCO Annual Meeting 2017 43

May 17, 2017: Affimed to Present Data for Preclinical AFM24 Program at ASCO Annual Meeting and EACR-AACR-SIC Special Conference 44

May 17, 2017: Affimed to Present Data for Preclinical AFM26 Program at ASCO Annual Meeting and EACR-AACR-SIC Special Conference 45

Apr 05, 2017: Affimed Presents Data on MHC-peptide-targeting discovery program at the AACR Annual Meeting 2017 46

Apr 05, 2017: Affimed Presents Data on Preclinical Program AFM-26 at the AACR Annual Meeting 2017 47

Apr 05, 2017: Affimed Presents Data on Preclinical Program AFM24 at the AACR Annual Meeting 2017 48

Apr 05, 2017: Affimed Presents Preclinical Data on AFM13 at the AACR Annual Meeting 2017 49

Jan 11, 2017: Affimed Provides Update on NK-cell Engager Platform Including Lead Product Candidate AFM13 50

Jan 11, 2017: Affimed Provides Update on NK-cell Engager Platform Including Lead Product Candidate AFM24 52

Jan 11, 2017: Affimed Provides Update on NK-cell Engager Platform Including Lead Product Candidate AFM26 53

Appendix 54

Methodology 54

About GlobalData 54

Contact Us 54

Disclaimer 54


List Of Figure

List of Figures

Affimed GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Affimed GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Affimed GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Affimed GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Affimed GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Affimed GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Affimed GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Affimed GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Affimed GmbH, Pharmaceuticals & Healthcare, Key Facts 2

Affimed GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Affimed GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Affimed GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Affimed GmbH, Deals By Therapy Area, 2012 to YTD 2018 9

Affimed GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Amphivena Therapeutics Raises USD 14 Million In Series A Financing 11

Affimed Therapeutics Raises USD 20.2 Million In Series D Financing 12

Affimed Raises USD21.8 Million in Private Placement of Shares 14

Affimed Therapeutics Raises USD56 Million in IPO 15

Janssen Biotech Enters Into Option To Acquire Amphivena From Affirmed Therapeutics 17

Affimed GmbH, Key Competitors 18

Affimed GmbH, Key Employees 19

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Affimed GmbH, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Affimed GmbH (Affimed), formerly Affimed Therapeutics AG, a subsidiary of Affimed NV, is a clinical stage biopharmaceutical company which discovers and develops targeted cancer immunotherapies. The company's pipeline product candidates include AFM11, AFM12, AFM13, AFM21 and AFM22, among others. Its AFM13 is in Phase I trials for the treatment of Hodgkin's lymphoma; and AFM11 is in late formal pre-clinical development for the treatment of non-Hodgkin's lymphoma. Affimed's discovery portfolio also includes AFM15, HSAxCD3 in preclinical trials, and others. The company has operations with offices in Czech Republic and the US. Affimed is headquartered in Heidelberg, Baden-Wurttemberg, Germany.

Affimed GmbH-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Affimed GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Affimed GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Affimed GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Affimed GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Affimed GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Affimed GmbH, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Amphivena Therapeutics Raises USD 14 Million In Series A Financing 11

Affimed Therapeutics Raises USD 20.2 Million In Series D Financing 12

Equity Offering 14

Affimed Raises USD21.8 Million in Private Placement of Shares 14

Affimed Therapeutics Raises USD56 Million in IPO 15

Acquisition 17

Janssen Biotech Enters Into Option To Acquire Amphivena From Affirmed Therapeutics 17

Affimed GmbH-Key Competitors 18

Affimed GmbH-Key Employees 19

Affimed GmbH-Locations And Subsidiaries 20

Head Office 20

Recent Developments 21

Financial Announcements 21

Aug 08, 2018: Affimed reports financial results for second quarter 2018 and operational progress 21

May 15, 2018: Affimed Reports Financial Results for First Quarter 2018 24

Mar 20, 2018: Affimed Reports Financial Results for Fourth Quarter and Year End 2017 26

Corporate Communications 28

Mar 19, 2018: Affimed Appoints Dr. Leila Alland as Chief Medical Officer 28

Product News 29

May 03, 2018: Affimed Introduces ROCK Platform for Tailored Immune Cell Engagers 29

03/01/2017: Affimed to Present Data on AFM13 at the AACR Annual Meeting 2017 30

03/01/2017: Affimed to Present Data on lead candidate AFM24 at the AACR Annual Meeting 2017 31

03/01/2017: Affimed to Present Data on lead candidate AFM26 at the AACR Annual Meeting 2017 32

03/01/2017: Affimed to Present Data on Monoclonal Antibodies to Target HLA-A2 and CD3 for Oncology at the AACR Annual Meeting 2017 33

Clinical Trials 34

Jun 15, 2018: Affimed Announces Updated Data of AFM13 in Combination with Keytruda (Pembrolizumab) in Patients with Relapsed/Refractory Hodgkin Lymphoma Presented at EHA 34

Mar 15, 2018: Affimed to Present Data on AFM24 at AACR Annual Meeting 2018 35

Feb 01, 2018: Affimed Reports New Data for AFM13 from Two Separate Clinical Trials in Hodgkin and CD30-Positive Lymphomas 36

Dec 11, 2017: Affimed Presents Data From Phase 1b Combination Study of AFM13 With Pembrolizumab at ASH 38

Dec 11, 2017: Affimed Presents Preclinical Data on AFM26 at American Society of Hematology (Ash) Annual Meeting and Exposition 2017 40

Jun 27, 2017: Affimed Presents Preclinical Data on AFM24 at EACR-AACR-SIC 2017 41

Jun 27, 2017: Affimed Presents Preclinical Data on AFM26 at EACR-AACR-SIC 2017 42

Jun 06, 2017: Affimed Presents Data on First-in-Class BCMA-Targeting Immune Cell Engager AFM26 at ASCO Annual Meeting 2017 43

May 17, 2017: Affimed to Present Data for Preclinical AFM24 Program at ASCO Annual Meeting and EACR-AACR-SIC Special Conference 44

May 17, 2017: Affimed to Present Data for Preclinical AFM26 Program at ASCO Annual Meeting and EACR-AACR-SIC Special Conference 45

Apr 05, 2017: Affimed Presents Data on MHC-peptide-targeting discovery program at the AACR Annual Meeting 2017 46

Apr 05, 2017: Affimed Presents Data on Preclinical Program AFM-26 at the AACR Annual Meeting 2017 47

Apr 05, 2017: Affimed Presents Data on Preclinical Program AFM24 at the AACR Annual Meeting 2017 48

Apr 05, 2017: Affimed Presents Preclinical Data on AFM13 at the AACR Annual Meeting 2017 49

Jan 11, 2017: Affimed Provides Update on NK-cell Engager Platform Including Lead Product Candidate AFM13 50

Jan 11, 2017: Affimed Provides Update on NK-cell Engager Platform Including Lead Product Candidate AFM24 52

Jan 11, 2017: Affimed Provides Update on NK-cell Engager Platform Including Lead Product Candidate AFM26 53

Appendix 54

Methodology 54

About GlobalData 54

Contact Us 54

Disclaimer 54


List Of Figure

List of Figures

Affimed GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Affimed GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Affimed GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Affimed GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Affimed GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Affimed GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Affimed GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Affimed GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Affimed GmbH, Pharmaceuticals & Healthcare, Key Facts 2

Affimed GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Affimed GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Affimed GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Affimed GmbH, Deals By Therapy Area, 2012 to YTD 2018 9

Affimed GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Amphivena Therapeutics Raises USD 14 Million In Series A Financing 11

Affimed Therapeutics Raises USD 20.2 Million In Series D Financing 12

Affimed Raises USD21.8 Million in Private Placement of Shares 14

Affimed Therapeutics Raises USD56 Million in IPO 15

Janssen Biotech Enters Into Option To Acquire Amphivena From Affirmed Therapeutics 17

Affimed GmbH, Key Competitors 18

Affimed GmbH, Key Employees 19

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Affimed GmbH, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.